The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Novel “anti-reverse” cap analogs with superior translational properties
Open accessAbstract
Synthetic analogs of the 5′-terminal caps of eukaryotic mRNAs and snRNAs are used in elucidating such physiological processes as mRNA translation, pre-mRNA splicing, intracellular transport of mRNA and snRNAs, and mRNA turnover. Particularly useful are RNAs capped with synthetic analogs, which are produced by in vitro transcription of a DNA template using a bacteriophage RNA polymerase in the presence of ribonucleoside triphosphates and a cap dinucleotide such as m 7 Gp 3 G. Unfortunately, because of the presence of a 3′-OH on both the m 7 Guo and Guo moieties, up to half of the mRNAs contain caps incorporated in the reverse orientation. Previously we designed and synthesized two “anti-reverse” cap analogs (ARCAs), m 7 3′dGp 3 G and m 27,3′-O Gp 3 G, that cannot be incorporated in the reverse orientation because of modifications at the C3′ position of m 7 Guo. In the present study, we have synthesized seven new cap analogs modified in the C2′ and C3′ positions of m 7 Guo and in the number of phosphate residues, m 27,2′-O Gp 3 G, m 7 2′dGp 3 G, m 7 2′dGp 4 G, m 27,2′-O Gp 4 G, m 27,3′-O Gp 4 G, m 7 Gp 5 G, and m 27,3′-O Gp 5 G. These were analyzed for conformation in solution, binding affinity to eIF4E, inhibition of in vitro translation, degree of reverse capping during in vitro transcription, capping efficiency, and the ability to stimulate cap-dependent translation in vitro when incorporated into mRNA. The results indicate that modifications at C2′, like those at C3′, prevent reverse incorporation, that tetra- and pentaphosphate cap analogs bind eIF4E and inhibit translation more strongly than their triphosphate counterparts, and that tetraphosphate ARCAs promote cap-dependent translation more effectively than previous cap analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121
The relationship between proton-proton NMR coupling constants and substituent electronegativities—I
Haasnoot, C. A. G., de Leeuw, F. A. A. M., & Altona, C. (1980) · Tetrahedron · doi:10.1016/0040-4020(80)80155-4 · Cited by 2,035
Translational control of gene expression
Sonenberg, N., Hershey, J. W. B., & Mathews, M. B. (2000) · Cold Spring Harbor Laboratory eBooks · Cited by 1,379
Cocrystal Structure of the Messenger RNA 5′ Cap-Binding Protein (eIF4E) Bound to 7-methyl-GDP
Marcotrigiano, J., Gingras, A.-C., Sonenberg, N., & Burley, S. K. (1997) · Cell · doi:10.1016/s0092-8674(00)80280-9 · Cited by 678
Forces contributing to the conformational stability of proteins
Pace, C. N., Shirley, B. A., McNutt, M., & Gajiwala, K. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.1.8566551 · Cited by 650
Recognition of cap structure in splicing in vitro of mRNA precursors
Konarska, M. M., Padgett, R. A., & Sharp, P. A. (1984) · Cell · doi:10.1016/0092-8674(84)90268-x · Cited by 568
A nuclear cap binding protein complex involved in pre-mRNA splicing
Izaurralde, E., Lewis, J., McGuigan, C., Jankowska, M., Darzynkiewicz, E., & Mattaj, I. W. (1994) · Cell · doi:10.1016/0092-8674(94)90530-4 · Cited by 517
Self-citationViral and cellular mRNA capping: Past and prospects
Furuichi, Y., & Shatkin, A. J. (2000) · Advances in Virus Research · doi:10.1016/s0065-3527(00)55003-9 · Cited by 404
Niedzwiecka, A., Marcotrigiano, J., Stepinski, J., Jankowska-Anyszka, M., Wyslouch-Cieszynska, A., Dadlez, M., Gingras, A.-C., Mak, P., Darzynkiewicz, E., Sonenberg, N., et al. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00328-5 · Cited by 380
Self-citationStructure of translation factor elF4E bound to m7GDP and interaction with 4E-binding protein
Matsuo, H., Li, H., McGuire, A. M., Fletcher, C. M., Gingras, A.-C., Sonenberg, N., & Wagner, G. (1997) · Nature Structural Biology · doi:10.1038/nsb0997-717 · Cited by 377
Cited by
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
“To avoid this, the so‐called ARCA with only one 3’‐OH group instead of two 3’‐OH groups (ARCAs; m27,3’−OGpppG) has been introduced to prevent incorporation in the opposite orientation [43].”
Method
Metadata
- Authors
- JEMIELITY, J., FOWLER, T., ZUBEREK, J., STEPINSKI, J., LEWDOROWICZ, M., NIEDZWIECKA, A., STOLARSKI, R., DARZYNKIEWICZ, E., & RHOADS, R. E.
- Venue
- RNA
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-08-15
- Volume
- 9
- Issue
- 9
- Pages
- 1108-1122
- ISSN
- 1355-8382 (ISSN-L)
- 1469-9001
- OpenAlex
- W2162165801
- Cited by
- 263
- References
- 47
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel “anti-reverse” cap analogs with superior translational properties. https://app.cochat.ai/papers/10.1261/rna.5430403
- The paper
- JEMIELITY, J., FOWLER, T., ZUBEREK, J., STEPINSKI, J., LEWDOROWICZ, M., NIEDZWIECKA, A., STOLARSKI, R., DARZYNKIEWICZ, E., & RHOADS, R. E. (2003). Novel “anti-reverse” cap analogs with superior translational properties. RNA. https://doi.org/10.1261/rna.5430403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
